Incyte (INCY) Cash from Operations Growth (3y) (2013 - 2026)
Powered by 
Analysis
Incyte (INCY) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -0.27% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -7.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 16.85% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 52.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 96.08% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 6.22% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.23% |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 18.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.31% |
| Mar 31, 2026 | 76.49% |
| Dec 31, 2025 | 24.19% |
| Sep 30, 2025 | 23.58% |
| Jun 30, 2025 | -36.43% |
| Mar 31, 2025 | 7.24% |
| Dec 31, 2024 | 48.95% |
| Sep 30, 2024 | 6.81% |
| Jun 30, 2024 | -74.66% |
| Mar 31, 2024 | 2.02% |
| Dec 31, 2023 | 11.24% |
| Sep 30, 2023 | -6.72% |
| Jun 30, 2023 | 4.40% |
| Mar 31, 2023 | 46.34% |
| Dec 31, 2022 | 29.17% |
| Sep 30, 2022 | 3.10% |
| Jun 30, 2022 | 4.42% |
| Mar 31, 2022 | 11.49% |
| Dec 31, 2021 | 11.22% |
| Sep 30, 2021 | 8.60% |